Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on December 5, 2017. The report discloses a material corporate governance event: the promotion of an executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Scott Braunstein, MD, as Chief Operating Officer (COO), effective December 11, 2017. Dr. Braunstein was previously the Senior Vice President, Strategy and Corporate Development.
Management Commentary and Compensation Details
In connection with the promotion, the following compensatory arrangements were established effective for 2018:
- Base Salary: Increased to $500,000 annually.
- Target Bonus: Increased to 50% of the base salary.
- Equity Grant: Options to purchase 60,000 shares of common stock.
- Exercise Price: Set at the closing price on the second full trading day in January 2018.
- Vesting Schedule: 25% vests on the first anniversary of the grant date; the remaining 75% vests in equal quarterly installments over the subsequent three years.
Dr. Braunstein brings significant experience from J.P. Morgan Asset Management, Everpoint Asset Management, and Aisling Capital, with a background in healthcare investment and strategy.
Investor Verification Checklist
- Verify the effective date of the COO appointment (December 11, 2017).
- Confirm the specific vesting schedule and exercise price determination date for the 60,000 stock options.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.